The Clarity to Empower Clinical Research

Intelligence ▸ Technology ▸ Expertise

Who We Are

We are a leading provider of intelligent technology, insights and expertise that reduce the barriers and time involved in designing and conducting clinical trials and research, from feasibility and site selection to patient screening and matching. We harness vast sets of oncology and patient data to bring a new level of clarity to the process—opening more opportunities for patients and accelerating scientific discoveries.

Our Solutions

With our intelligent technology, insights and dedicated clinical engagement specialists, sites are matching more patients and growing research programs.

The Inteliquet software platform
Accelerate clinical trial and research success with powerful software to digitize trials and screen and match patients.

Real-time Patient Comparisons
With access to millions of patients and treatment details, providers can conduct rapid, accurate comparisons with hundreds of their patients' peers.

Clinical Engagement Expertise
A dedicated clinical engagement specialist trains, supports and works side by side with providers to ensure optimal success with the Inteliquet Software Platform.

90%
Time savings reported by clinical research staff with Inteliquery when determining if patient populations support specific trials.

Capabilities

▸ Advanced technology platform increases efficiency of patient screening

▸ Vast data asset and real-world evidence to quickly identify possible patients

▸ User-curated Watch List helps ensure patients do not miss a clinical trial opportunity at time of treatment decisions

▸ Patient matching to the biomarker level, substantially reducing the number of false positives

▸ Applications to facilitate collaboration between CROs and Providers

▸ Efficient trial site identification and selection

▸ Dynamic protocol feasibility

inteliquet

The Inteliquet Clinical Consortium

4.7+ million
patients

1.2+ million
cancer patients

86+ million
treatment details

▸ Millions of patients sorted by diagnoses, treatment details, outcomes, and biomarkers.

▸ Hundreds of participating providers at leading U.S. healthcare institutions.

▸ Access to a portfolio of hundreds of funded studies directly from our partners.

▸ Works seamlessly and securely with different EHR systems.

▸ Rapid, accurate, predictive knowledge supports most promising care to patients.

Scientific Advisory Board

We work with some of the top minds and thought leaders across many areas of oncology, translational research and genomics, and pathology. Our Scientific Board helps guide our mission, vision and strategies and ensures we are bringing the best to bear to providers, researchers and patients everywhere.

Barbara McAneny, MD, ASCO, MACP
President, American Medical Association (AMA)

Daniel D. Von Hoff, MD, FACP
Physician in Chief, Distinguished Professor of the Translational Research Division at TGen (Translational Genomics Research Institute)

Paul A. Bunn, Jr., MD
Distinguished Professor of Medicine and the James Dudley endowed Professor of Lung Cancer research at the University of Colorado Cancer Center and School of Medicine

Noah M. Hahn, MD
Associate Professor of Medicine at the Department of Oncology and the Department of Urology at Johns Hopkins University School of Medicine

Stanley R. Hamilton, MD, FACP, AGAF
Professor and Head of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center (UTMDACC)

W Jeff Edenfield, MD
Greenville Health System Institute for Translational Oncology Research

Patients First

We believe that every patient deserves access to a clinical trial. Clinical trials have the potential to save and extend lives, improve the standard of care, and ultimately find lasting solutions for cancer and other critical diseases. That's what drive us—every day we help ensure no patient goes without access to a clinical trial thus accelerating the availability of promising new treatments.

Contact us
info@inteliquet.com • inteliquet.com

inteliquet